Received Jul 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HIBV | HIB (ACTHIB) | SANOFI PASTEUR | 1 | UK169A | OT / RL |
acthib that was reconstituted with sterile water, a diluent from another vaccine, and it was administered to a patient with no reported adverse event; Initial information received on 15-Jul-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 15 months old male patient received HIB (PRP/T) vaccine [ACT-HIB] that was reconstituted with sterile water, a diluent from another vaccine, and it was administered to a patient with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included measles vaccine, mumps vaccine, rubella vaccine (MMR) and varicella zoster vaccine for Immunisation. On 10-Jul-2025, the patient received dose 1 of 0.5 ml suspect HIB (PRP/T) vaccine Powder and solvent for solution for injection of standard strength, frequency once with lot UK169A and expiry date 28-Feb-2026 via intramuscular route in the right thigh for immunisation that was reconstituted with sterile water, a diluent from another vaccine, and it was administered to a patient with no reported adverse event (product preparation error) (Latency same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
MMR; VARICELLA ZOSTER VACCINE